OpGen Q2 Revenues Drop 64 Percent as Business Focus Continues to Shift | GenomeWeb

NEW YORK (GenomeWeb) – OpGen reported after the close of the market on Thursday a 64 percent dip in its second quarter revenues.

For the three months ended June 30, the Gaithersburg, Maryland-based microbial genetics testing and analysis firm reported $375,146 in revenues, down from $1.1 million for the same quarter a year ago.

OpGen's Q2 product sales rose to $319,171 from $272,538 in the year-ago period, while its laboratory services sales fell to $28,195 from $121,899. Meantime, revenues from collaborations fell to $27,780 from $677,780 year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.